Empagliflozin and Dapagliflozin Reduce ROS Generation and Restore NO Bioavailability in Tumor Necrosis Factor α-Stimulated Human Coronary Arterial Endothelial Cells
Cellular Physiology and Biochemistry2019Vol. 53(5), pp. 865–886
Citations Over TimeTop 1% of 2019 papers
Laween Uthman, Anna Homayr, Rio P. Juni, Eva Spin, Raphaela P. Kerindongo, Marleen Boomsma, Markus W. Hollmann, Benedikt Preckel, Pieter Koolwijk, Victor W.M. van Hinsbergh, Coert J. Zuurbier, Martin Albrecht, Nina C. Weber
Abstract
These data suggest that EMPA and DAPA rather restore NO bioavailability by inhibiting ROS generation than by affecting eNOS expression or signaling, barrier function and adhesion molecules expression in TNFα-induced endothelial cells. Furthermore, the observed effects cannot be ascribed to the inhibition of SGLT2 in endothelial cells.
Related Papers
- → Empagliflozin and Kidney Function Decline in Patients with Type 2 Diabetes: A Slope Analysis from the EMPA-REG OUTCOME Trial(2018)196 cited
- → Cost-Effectiveness of Empagliflozin (Jardiance) in the Treatment of Patients with Type 2 Diabetes Mellitus (T2DM) in the UK Based on Empa-Reg Outcome Data(2016)12 cited
- → CONSISTENT EFFECT OF EMPAGLIFLOZIN ON COMPOSITE OUTCOMES RELATED TO HEART FAILURE: RESULTS FROM EMPA-REG OUTCOME(2017)4 cited
- → Are the Cardiovascular (CV) Risk Reductions Seen with Empagliflozin in the EMPA-REG OUTCOME Trial Explained by Conventional CV Risk Factors?(2017)1 cited
- → Effect of Empagliflozin on Total Events of Myocardial Infarctions by Subtype in the EMPA-REG OUTCOME Trial(2021)